About Humacyte, Inc.
https://www.humacyte.comHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
CEO
Laura E. Niklason
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.9M
Value:$11.29M
VANGUARD GROUP INC
Shares:7.52M
Value:$8.57M
BLACKROCK INC.
Shares:7.14M
Value:$8.14M
Summary
Showing Top 3 of 156
About Humacyte, Inc.
https://www.humacyte.comHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $753K ▲ | $24.88M ▼ | $-17.51M ▲ | -2.33K% ▲ | $-0.11 ▲ | $-13.03M ▲ |
| Q2-2025 | $301K ▼ | $27.95M ▲ | $-37.66M ▼ | -12.51K% ▼ | $-0.24 ▼ | $-33.25M ▼ |
| Q1-2025 | $517K ▼ | $21.72M ▼ | $39.14M ▲ | 7.57K% ▲ | $0.28 ▲ | $43.97M ▲ |
| Q4-2024 | $7.23M ▲ | $31.7M ▲ | $-20.94M ▲ | -289.71% ▼ | $-0.16 ▲ | $-16.62M ▲ |
| Q3-2024 | $0 | $28.42M | $-39.2M | 0% | $-0.33 | $-34.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $19.49M ▼ | $91.51M ▼ | $96.26M ▼ | $-4.75M ▼ |
| Q2-2025 | $38.03M ▼ | $138.79M ▼ | $134.74M ▲ | $4.05M ▼ |
| Q1-2025 | $62.85M ▲ | $162.55M ▲ | $126.51M ▼ | $36.04M ▲ |
| Q4-2024 | $44.94M ▲ | $137.87M ▲ | $190.54M ▲ | $-52.67M ▲ |
| Q3-2024 | $20.57M | $114.76M | $178.49M | $-63.72M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.51M ▲ | $-23.9M ▲ | $-49K ▲ | $-44.59M ▼ | $-68.54M ▼ | $-23.95M ▲ |
| Q2-2025 | $-37.66M ▼ | $-26.41M ▲ | $-568K ▼ | $2.17M ▼ | $-24.96M ▼ | $-26.98M ▲ |
| Q1-2025 | $39.14M ▲ | $-28.6M ▼ | $-228K ▼ | $46.74M ▼ | $17.91M ▼ | $-28.83M ▼ |
| Q4-2024 | $-20.94M ▲ | $-26.58M ▼ | $-63K ▲ | $51.01M ▲ | $24.37M ▲ | $-26.64M ▼ |
| Q3-2024 | $-39.2M | $-22.91M | $-934K | $849K | $-22.99M | $-23.84M |
CEO
Laura E. Niklason
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 68
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:9.9M
Value:$11.29M
VANGUARD GROUP INC
Shares:7.52M
Value:$8.57M
BLACKROCK INC.
Shares:7.14M
Value:$8.14M
Summary
Showing Top 3 of 156